Palvella Therapeutics

Palvella Therapeutics is a Wayne, Pennsylvania-based clinical-stage biopharmaceutical company developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations, anchored by its QTORIN proprietary topical delivery platform. The lead asset QTORIN 3.9% rapamycin anhydrous gel is being evaluated in the Phase 3 SELVA trial for microcystic lymphatic malformations (51 patients enrolled against a 40-patient target, with topline results expected in March 2026 and a rolling NDA submission planned for H2 2026 if endpoints are met). On June 29, 2026 Palvella submitted the first module of a rolling NDA to the FDA for QTORIN rapamycin in microcystic lymphatic malformations, and on July 14, 2026 the company filed a new corporate presentation on the SEC platform outlining QTORIN platform progress and growth plans. The QTORIN pitavastatin program is protected by a Yale-licensed U.S. patent providing protection into 2043. Palvella reported cash of $262M and a $1.96B market capitalization as of mid-July 2026.